GSK Confirms Arexvy Price And US Contract Negotiations Ahead Of Launch

Talks Crucial To Launch Success

GSK is gearing up for its most important new product launch in years and hopes US payers will buy into Arexvy’s likely higher price than Pfizer’s rival RSV vaccine.

GSK

GSK is gearing up for the launch of Arexvy, its respiratory syncytial virus (RSV) vaccine for older people, and is counting on efficacy data to persuade US payers of its value in ongoing contract negotiations.

Arexvy is the UK-headquartered company’s most important launch for many years, as it hopes the vaccine can generate around $3bn in annual revenues once it reaches its peak. However, it faces competition from Abrysvo, Pfizer’s also recently approved rival

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Merck’s Welireg Adrenal Tumor Rollout Targets Specialized Centers

 

The drugmaker won US FDA approval for the HIF-2α inhibitor in pheochromocytoma and paraganglioma, a rare cancer of the adrenal glands, in adolescents and adults.

China Biopharma Podcast

 
• By 

Join our China-based editors Dexter Yan and Xu Hu in this Chinese-language podcast looking at some of their recent interviews and other key coverage.

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

More from Therapy Areas

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By 

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Multiple Launches Help Lilly’s Japan Growth

 
• By 

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.